The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biomark Res
Hlavní autoři: Wu, Yongfeng, Xu, Jinming, Xu, Jiawei, Wang, Yiqing, Wang, Luming, Lv, Wang, Hu, Jian
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Letter to the Editor
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7146978/
https://ncbi.nlm.nih.gov/pubmed/32308981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00188-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky